普瑞巴林对原发性三叉神经痛患者血浆P物质和β-内啡肽的影响

Influence of pregabalin on plasma substance P and beta-endorphin in patients with trigeminal neuralgia

目的:通过观察普瑞巴林(PGB)与卡马西平(CBZ)对原发性三叉神经痛患者的血浆P物质(SP)和β-内啡肽(β-EP)变化以及疼痛视觉模拟评分(VAS)的变化,评估普瑞巴PGB治疗原发性三叉神经痛的安全性及有效性。方法:121例原发性三叉神经痛患者按数字表法随机分为2组,其中PGB组59例,CBZ组62例。2组分别从低剂量开始给药,观察疗效及不良反应至第4周末,2组在治疗前和结束时使用放免法检测血浆SP和β-EP水平,并进行VAS评分。结果:PGB组总有效率89.8%,CBZ组为72.4%,2组差异有统计学意义(P<0.05)。治疗后2组血浆β-EP水平均呈上升趋势,血浆SP水平均呈下降趋势,PGB组较CBZ组更为明显(P<0.05)。PGB组不良反应发生率30.5%(18/59),明显低于CBZ组58.1%(36/62)。结论:PGB治疗三叉神经痛有效性和安全性均优于CBZ。

OBJEC-TIVE To evaluate the efficacy and safety of pregabalin （PGB）for the patients with primary trigeminal neu- ralgia（PTN）. METHODS 121 patients with PTN were randomly divided into PGB group（59 cases） and carbamazepine（CBZ） group（62 cases）. Both groups were administered with low dose at first , then observed the therapeutic effect and adverse reac- tions until termination of the fourth week. The plasma SP and 13-EP levels were detected by radioimmunoassay before adminis- tration, also at the termination, while the visual analogue scales（VAS） were measured. RESULTS The clinical efficiency of PGB was 89. 80/00, that of CBZ was 72. 4%, which was significantly different between the two groups（P〈0. 05）. The treat- ments reduced plasma SP level while increasing plasma 13-EP level in the 2 groups. The change of PGB group was more obvious than that of CBZ group（P〈0. 05）. The incidence rate of adverse reactions by PGB（30. 5%, 18/59） was less than that by CI3Z （58. 1% ,36/62）（P〈0. 05）. CONCLUSION The efficacy and safety of PGB for the patients with PTN surf）ass that of CBZ.